Last 7 days
12.5%
Last 30 days
21.5%
Last 90 days
41.0%
Trailing 12 Months
-16.9%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-09-08 | GRAYZEL DAVID S. | back to issuer | - | - | -2,945,450 | - |
2023-09-08 | ROSS ROBERT W. | back to issuer | - | - | -83,193 | chief executive officer |
2023-09-08 | ONEILL ALISON | back to issuer | - | - | -56,686 | chief medical officer |
2023-09-08 | Goater Jeff | back to issuer | - | - | -129,222 | - |
2023-09-08 | FEES JESSICA | back to issuer | - | - | -101,915 | chief financial officer |
2023-09-08 | RATH HENRY C. | back to issuer | - | - | -44,971 | chief business officer |
2023-09-08 | Adams Chandra | back to issuer | - | - | -23,884 | deputy gc |
2023-09-08 | Palombella Vito J. | back to issuer | - | - | -87,212 | chief scientific officer |
2023-09-08 | Sigal Charles Elliott | back to issuer | - | - | -45,453 | - |
2023-08-01 | Adams Chandra | sold | -3,666 | 0.94 | -3,901 | deputy gc |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | sold off | -100 | -20,000 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | unchanged | - | 1,816 | 9,104 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 1.85 | 162 | 765 | -% |
2023-08-15 | Cornerstone Planning Group LLC | new | - | 217 | 217 | -% |
2023-08-15 | Formidable Asset Management, LLC | unchanged | - | 2,000 | 13,000 | -% |
2023-08-15 | Ground Swell Capital, LLC | new | - | 17,662 | 17,662 | 0.02% |
2023-08-15 | GOLDMAN SACHS GROUP INC | sold off | -100 | -442,738 | - | -% |
2023-08-14 | MACQUARIE GROUP LTD | unchanged | - | 59,000 | 304,000 | -% |
2023-08-14 | FEDERATED HERMES, INC. | unchanged | - | 451 | 2,294 | -% |
2023-08-14 | TWO SIGMA ADVISERS, LP | reduced | -25.57 | -1,795 | 22,523 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Jul 20, 2023 | adar1 partners, lp | 5.24% | 3,183,242 | SC 13G | |
Feb 13, 2023 | ecor1 capital, llc | 6.5% | 3,924,713 | SC 13G/A | |
Jan 31, 2023 | atlas venture fund ix, l.p. | 4.87% | 2,945,453 | SC 13G/A | |
May 09, 2022 | blackrock inc. | 4.6% | 2,502,271 | SC 13G | |
Mar 14, 2022 | ecor1 capital, llc | 9.9% | 4,653,000 | SC 13G | |
Feb 10, 2022 | eli lilly & co | 3.5% | 1,593,997 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 11.54% | 5,326,127 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 04, 2022 | blackrock inc. | 5.6% | 2,562,685 | SC 13G | |
Jan 25, 2022 | atlas venture fund ix, l.p. | 6.38% | 2,945,453 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 18, 2023 | 15-12G | 15-12G | |
Sep 12, 2023 | EFFECT | EFFECT | |
Sep 12, 2023 | EFFECT | EFFECT | |
Sep 08, 2023 | S-8 POS | Employee Benefits Plan | |
Sep 08, 2023 | S-8 POS | Employee Benefits Plan | |
Sep 08, 2023 | S-8 POS | Employee Benefits Plan | |
Sep 08, 2023 | POS AM | POS AM | |
Sep 08, 2023 | POS AM | POS AM | |
Sep 08, 2023 | 8-K | Current Report | |
Sep 08, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 143.9B | 26.6B | 4.94% | 20.46% | 18.04 | 5.41 | 0.75% | 21.34% |
GILD | 94.2B | 27.4B | -1.73% | 23.33% | 17.17 | 3.44 | -0.48% | 32.56% |
MRNA | 37.4B | 10.7B | -12.34% | -18.02% | 30.97 | 3.51 | -53.67% | -91.41% |
BIIB | 37.3B | 10.0B | -2.41% | 31.83% | 14.01 | 3.74 | -6.23% | 29.40% |
MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 6.64% | 14.01% | 63.44 | 6.69 | 29.01% | 1345.90% |
BBIO | 4.3B | - | -10.44% | 191.13% | -7.34 | 48.33 | 54.84% | -12.96% |
DNLI | 2.9B | - | -7.08% | -17.64% | -22.89 | 37.44 | 122.90% | 54.78% |
BEAM | 1.8B | 80.2M | 1.68% | -49.31% | -5.62 | 22.95 | 42.17% | -39.82% |
SMALL-CAP | ||||||||
RCUS | 1.4B | 121.2M | -15.01% | -21.70% | -4.98 | 11.8 | -70.36% | -531.73% |
REPL | 941.3M | 15.3M | -22.34% | -0.87% | -5.18 | 61.48 | 1090.59% | -36.57% |
NVAX | 670.5M | 1.6B | -11.68% | -62.32% | -1.14 | 0.42 | 23.74% | 60.24% |
FATE | 199.0M | - | -23.19% | -90.40% | -0.94 | 1.45 | 116.83% | 16.61% |
SGMO | 118.0M | - | -12.12% | -85.84% | -0.59 | 0.49 | 113.96% | -15.19% |
VXRT | 107.9M | 2.1M | -9.82% | -66.03% | -1.07 | 52.51 | 487.70% | -8.66% |
IBIO | 3.7M | - | -11.16% | -96.28% | -0.05 | 3.21 | - | -129.46% |
-35.5%
-46.7%
100%
100%
100%
Y-axis is the maximum loss one would have experienced if Surface Oncology was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Revenue | -100.0% | - | 30,000,000 | 23,171,750 | 16,343,500 | 9,515,250 | 2,687,000 | 33,555,750 | 64,424,500 | 95,293,250 | 126,162,000 | - | - | - | - | - | - | - | - | - | - | 56,649,000 |
Operating Expenses | -2.7% | 89,386,000 | 91,869,000 | 94,213,000 | 91,199,000 | 85,678,000 | 78,700,000 | 74,772,000 | 69,246,000 | 64,686,000 | 64,576,000 | 61,747,000 | 65,289,000 | 69,399,000 | 72,726,000 | 71,300,000 | 73,160,000 | 73,518,000 | 68,568,000 | 72,337,000 | 69,329,000 | 63,042,000 |
S&GA Expenses | 6.0% | 26,362,000 | 24,866,000 | 26,175,000 | 26,018,000 | 26,026,000 | 25,128,000 | 26,794,000 | 25,851,000 | 24,412,000 | 23,558,000 | 19,800,000 | 19,880,000 | 20,302,000 | 20,608,000 | 20,318,000 | 19,311,000 | 17,807,000 | 16,076,000 | 14,084,000 | 14,758,000 | 12,849,000 |
R&D Expenses | -10.8% | 59,790,000 | 67,003,000 | 68,038,000 | 65,181,000 | 59,652,000 | 53,572,000 | 47,978,000 | 43,395,000 | 40,274,000 | 41,018,000 | 41,947,000 | 45,409,000 | 49,097,000 | 52,118,000 | 50,982,000 | 53,849,000 | 55,711,000 | 52,492,000 | 58,253,000 | 54,571,000 | 50,193,000 |
EBITDA | - | - | - | - | -74,506,000 | -74,773,000 | -74,370,000 | - | - | 62,700,000 | 62,068,000 | -50,832,000 | -52,256,000 | -52,523,666 | -53,004,000 | -4,908,000 | -5,027,000 | -5,141,000 | - | - | - | - |
EBITDA Margin | - | - | - | - | -27.73 | -27.83 | -27.68 | - | - | 0.50 | 0.49 | -0.90 | -0.92 | -0.93 | -0.94 | -0.09 | -0.09 | -0.09 | - | - | - | - |
Interest Expenses | 83.4% | 5,771,000 | 3,146,000 | 2,929,000 | 2,521,000 | 2,204,000 | 2,546,000 | 2,479,000 | 3,527,000 | 3,538,000 | 2,855,000 | 2,381,000 | 912,000 | 646,667 | 145,000 | - | - | - | - | - | - | - |
Earnings Before Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2,482,666 | 1,728,000 | 14,318,667 |
EBT Margin | - | - | - | - | -29.21 | -29.21 | -29.21 | - | - | 0.47 | 0.47 | -0.97 | -0.97 | -0.97 | -0.97 | -0.12 | -0.12 | -0.12 | - | - | - | - |
Net Income | -45.5% | -92,505,000 | -63,586,000 | -66,304,000 | -62,957,000 | -56,725,000 | -78,485,000 | 12,913,000 | 17,032,000 | 21,206,000 | 59,337,000 | -23,965,000 | -25,069,000 | -28,020,000 | -54,789,000 | -43,570,000 | -43,914,000 | -42,008,000 | -6,597,000 | -17,635,000 | -14,818,000 | -5,539,000 |
Net Income Margin | 100.0% | - | -2.12 | -2.20 | -23.43 | -21.11 | -29.21 | 0.38 | 0.26 | 0.17 | 0.47 | -0.42 | -0.44 | -0.49 | - | - | - | - | - | - | - | - |
Free Cashflow | 100.0% | - | -60,049,000 | -53,928,000 | -50,352,000 | -67,102,000 | -62,464,000 | 25,749,000 | 30,796,000 | 26,590,000 | 29,954,000 | -55,803,000 | -60,203,000 | -58,093,000 | -61,678,000 | - | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | -51.8% | 66.00 | 137 | 160 | 182 | 194 | 218 | 191 | 189 | 206 | 215 | 217 | 145 | 155 | 131 | 132 | 139 | 155 | 171 | 174 | 186 | 202 |
Current Assets | -43.5% | 61.00 | 107 | 129 | 150 | 162 | 184 | 157 | 155 | 171 | 179 | 181 | 108 | 118 | 93.00 | 108 | 114 | 130 | 145 | 165 | 178 | 194 |
Cash Equivalents | -48.8% | 15.00 | 29.00 | 51.00 | 65.00 | 75.00 | 66.00 | 56.00 | 61.00 | 83.00 | 101 | 175 | 99.00 | 93.00 | 56.00 | 47.00 | 39.00 | 38.00 | 41.00 | 83.00 | 42.00 | 51.00 |
Net PPE | -44.6% | 2.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 6.00 | 7.00 | 7.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 |
Liabilities | -72.5% | 17.00 | 61.00 | 67.00 | 69.00 | 68.00 | 71.00 | 72.00 | 57.00 | 57.00 | 56.00 | 61.00 | 59.00 | 57.00 | 50.00 | 75.00 | 70.00 | 71.00 | 70.00 | 71.00 | 80.00 | 80.00 |
Current Liabilities | 14.1% | 17.00 | 15.00 | 16.00 | 18.00 | 20.00 | 20.00 | 20.00 | 16.00 | 19.00 | 15.00 | 18.00 | 14.00 | 11.00 | 13.00 | 19.00 | 16.00 | 15.00 | 13.00 | 27.00 | 28.00 | 25.00 |
Shareholder's Equity | -35.1% | 49.00 | 76.00 | 93.00 | 113 | 126 | 147 | 119 | 131 | 148 | 159 | 156 | 86.00 | 98.00 | 82.00 | 57.00 | 69.00 | 84.00 | 100 | 103 | 106 | 122 |
Retained Earnings | -12.6% | -252 | -224 | -204 | -183 | -159 | -134 | -140 | -116 | -96.80 | -77.82 | -62.26 | -129 | -113 | -99.02 | -121 | -105 | -88.76 | -71.00 | -66.81 | -62.07 | -44.85 |
Additional Paid-In Capital | 0.4% | 302 | 300 | 299 | 297 | 287 | 282 | 260 | 248 | 245 | 237 | 218 | 216 | 211 | 180 | 178 | 174 | 173 | 171 | 170 | 168 | 167 |
Shares Outstanding | 0.0% | 61.00 | 61.00 | 61.00 | 61.00 | 55.00 | 49.00 | 47.00 | 45.00 | 44.00 | 42.00 | 41.00 | 40.00 | 33.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 17.00 | 22.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | -40.6% | -83,581 | -59,425 | -59,552 | -53,655 | -50,086 | -66,947 | -62,344 | 25,822 | 30,816 | 26,610 | 29,997 | -55,650 | -59,779 | -57,408 | -60,140 | -60,744 | -58,497 | -62,541 | -13,222 | -13,746 | -11,064 |
Share Based Compensation | -12.7% | 6,117 | 7,004 | 7,223 | 7,547 | 7,825 | 8,031 | 8,546 | 8,655 | 8,574 | 8,295 | 7,765 | 7,358 | 6,961 | 6,446 | 5,991 | 5,668 | 5,316 | 5,321 | 5,217 | 4,668 | 6,258 |
Cashflow From Investing | 252.7% | 41,353 | 11,726 | 22,757 | 5,471 | -3,032 | -16,153 | -99,252 | -86,512 | -61,981 | -37,154 | 58,307 | 70,135 | 68,938 | 65,294 | 16,965 | 57,136 | 44,931 | -65,806 | -36,584 | -85,139 | -85,846 |
Cashflow From Financing | -275.5% | -19,349 | 11,024 | 31,660 | 52,432 | 44,607 | 48,231 | 42,500 | 22,072 | 21,375 | 54,651 | 40,082 | 46,855 | 46,612 | 7,617 | 7,415 | 539 | 552 | 110,485 | 110,376 | 109,270 | 109,031 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
License-related revenue | $ 0 | $ 0 | $ 0 | $ 30,000 |
Operating expenses: | ||||
Research and development | 13,831 | 18,198 | 27,608 | 34,822 |
General and administrative | 8,576 | 6,426 | 14,460 | 12,967 |
Restructuring charges | 3,234 | 0 | 3,234 | 0 |
Total operating expenses | 25,641 | 24,624 | 45,302 | 47,789 |
Loss from operations | (25,641) | (24,624) | (45,302) | (17,789) |
Interest expense | (3,108) | (733) | (4,040) | (1,415) |
Other income (expense), net | 557 | 144 | 1,409 | 190 |
Net loss | $ (28,192) | $ (25,213) | $ (47,933) | $ (19,014) |
Net loss per share — basic (in dollars per share) | $ (0.46) | $ (0.46) | $ (0.79) | $ (0.37) |
Net loss per share — diluted (in dollars per share) | $ (0.46) | $ (0.46) | $ (0.79) | $ (0.37) |
Weighted average common shares outstanding— basic (in shares) | 60,717,899 | 54,654,822 | 60,673,195 | 51,647,148 |
Weighted average common shares outstanding— diluted (in shares) | 60,717,899 | 54,654,822 | 60,673,195 | 51,647,148 |
Comprehensive loss: | ||||
Net loss | $ (28,192) | $ (25,213) | $ (47,933) | $ (19,014) |
Other comprehensive loss: | ||||
Unrealized gain (loss) on marketable securities, net of tax of $0 | 348 | (259) | 794 | (949) |
Comprehensive loss | $ (27,844) | $ (25,472) | $ (47,139) | $ (19,963) |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 14,842 | $ 50,910 |
Marketable securities | 41,416 | 73,913 |
Prepaid expenses and other current assets | 4,330 | 4,317 |
Total current assets | 60,588 | 129,140 |
Property and equipment, net | 2,499 | 4,866 |
Operating lease right-of-use asset | 2,919 | 24,307 |
Restricted cash | 0 | 1,595 |
Other assets | 0 | 2 |
Total assets | 66,006 | 159,910 |
Current liabilities: | ||
Accounts payable | 609 | 256 |
Accrued expenses and other current liabilities | 6,731 | 10,214 |
Operating lease liability | 9,488 | 5,790 |
Total current liabilities | 16,828 | 16,260 |
Operating lease liability, non-current | 0 | 24,662 |
Convertible note payable, non-current | 0 | 25,585 |
Total liabilities | 16,828 | 66,507 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2023 and December 31, 2022, respectively; 60,730,274 and 60,578,956 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 6 | 6 |
Additional paid-in capital | 301,655 | 298,741 |
Accumulated other comprehensive loss | (221) | (1,015) |
Accumulated deficit | (252,262) | (204,329) |
Total stockholders’ equity | 49,178 | 93,403 |
Total liabilities and stockholders’ equity | $ 66,006 | $ 159,910 |